New England Independent Review Board

New England Independent Review Board is dedicated to ethical oversight in clinical research, specializing in Institutional Review Board (IRB) services to ensure participant safety and regulatory compliance across various therapeutic areas. Founded in 1988 and headquartered in Newton, US, New England Independent Review Board focuses on ethical review services for clinical research. The company was acquired by The Western Institutional Review Board in August 2014, enhancing its operational scope within the clinical research sector. New England Independent Review Board offers a comprehensive suite of services centered around ethical review and oversight in clinical research, primarily focusing on IRB and Institutional Biosafety Committee (IBC) reviews.

Their expedited IRB review services prioritize participant safety and compliance with regulatory standards. The client base includes pharmaceutical and biotech companies, academic institutions, and clinical research organizations (CROs), benefiting from tailored support across various therapeutic areas, including oncology and cardiovascular diseases. The company's services are primarily marketed in North America, while also accommodating international clients needing compliance with U. S.

standards. New England Independent Review Board generates revenue through a structured model based on contracts for IRB and IBC review services, often partnering with research sponsors and CROs. This includes subscription-based pricing for ongoing review services or fees for individual study submissions, providing clients with timely feedback and ethical oversight essential to the clinical trial process. By emphasizing personalized service and efficient review timelines, the company fosters long-term relationships with clients, ensuring adherence to complex regulatory requirements while maintaining participant safety.

Following its acquisition in August 2014, New England Independent Review Board aims to leverage its enhanced capabilities to expand into new markets. Plans are underway to grow its service offerings in additional therapeutic areas and broaden geographic reach, specifically targeting European markets by 2025. The company is focused on utilizing the resources gained from its acquisition to develop new products aimed at improving service efficiency and regulatory compliance in clinical trials.